Neuvivo Names Michael McGrath Permanent CEO
The biopharmaceutical company, which is preparing a Phase 3 trial of NP001 for slow-progressing ALS, moves its interim leader into the top job.
Updated on Nov. 14, 2026 in Biotech

Neuvivo Inc. has appointed Michael McGrath as its permanent chief executive officer, after he served as interim CEO for 12 months following his October 2025 appointment by the Board of Directors. The Palo Alto, California company is completing financing for a Phase 3 trial of its drug candidate NP001 in slow-progressing amyotrophic lateral sclerosis (ALS).
Why it matters
The leadership change comes as Neuvivo works toward a pivotal trial, following a retrospective analysis of two Phase 2 studies that identified a patient subgroup and an FDA-supported path forward. For residents of Palo Alto, where Neuvivo is headquartered, the decision signals continuity for a local biotech company advancing a treatment for a serious neurological disease.
The company's retrospective analysis of two Phase 2 studies of NP001 identified a slow-progressing ALS subgroup representing approximately 40% of people with ALS. NP001 has received Orphan Drug and Fast Track Designations from the FDA, but the timeline for completing trial financing remains unset.
The players
Neuvivo Inc.
A privately held late clinical-stage biopharmaceutical company founded in 2020 and headquartered in Palo Alto, California, focused on developing NP001 for amyotrophic lateral sclerosis.
Michael McGrath
A neuroscientist and emeritus professor at the University of California, San Francisco, who began dementia research at San Francisco General Hospital and has spent roughly 40 years studying macrophages.
The details
McGrath was selected from the Chief Scientific Officer role to serve as interim CEO after being appointed by the Neuvivo Board of Directors in October 2025. Neuvivo, a privately held late clinical-stage biopharmaceutical company founded in 2020, held a Type C meeting with the FDA whose feedback supports a pivotal Phase 3 trial of NP001 in slow-progressing ALS.
Timeline
October 2025: The Neuvivo Board of Directors appointed McGrath as interim CEO.
Nov. 13, 2026: Neuvivo announced McGrath's appointment as permanent CEO.
Tech Race
NP001 has received Orphan Drug and Fast Track Designations from the FDA, which are federal programs designed to accelerate development of therapies for rare diseases. Neuvivo's move to a pivotal Phase 3 trial follows that regulatory path, with FDA feedback from a Type C meeting shaping the next stage.
For ALS patients and families, the company's plan to move NP001 into a pivotal trial in the slow-progressing subgroup could eventually lead to a new treatment option, though no timeline for availability has been set. Neuvivo's leadership decision does not change any current treatment access for patients.
The takeaway
A permanent leader at Neuvivo means the company's Phase 3 plans for NP001 now have a single executive steering them, and the next signals to watch are trial financing and CRO selection. Patients and observers should track those milestones rather than the leadership news alone.
What happens next
Neuvivo plans to complete financing for the Phase 3 trial, identify a contract research organization to run it, and participate in an application for NINDS grant funding to study NP001 in additional ALS patients.
Further reading
For more on the field behind this leadership change, explore Biotech coverage on Wisevoter.
Source note: This article includes information reported by Firstwordpharma.










